Pelvic exenteration: a review of the Gateshead experience 1974–1992

Pelvic exenteration is used as therapeutic option for advanced or recurrent cancer in the pelvis. We determined the complications of and the survival after pelvic exenteration. The study was performed as a retrospective cohort (n = 62) study from January 1, 1989, until January 1, 2000. Descriptive statistics were used. Survival was estimated according to the Kaplan–Meier life table. The operative mortality was 1.6%. Seventy-five percent of the patients had postoperative complications of which ileus and urinary tract infection were the most common. Late complications occurred in 83% of the patients. Recurrent disease was observed in 38% of the women, whereas 50% had died on January 1, 2000. Five-years disease-free and overall survival were 42% (confidence interval [CI] ± 14%) and 46% (CI ± 14%), respectively. Elderly patients (>70 years old) do not experience more complications. Despite considerable morbidity, pelvic exenteration is a therapeutic option for survival, even for patients of 70 years and older.

show abstract

“…Disease-free and overall survival at 5 years were comparable to previous reported rates (3)(4)(5)(6)(7)(8)(9) .…”

Section: Discussionsupporting

confidence: 85%

“…The perioperative mortality after pelvic exenteration has fallen to 0-10% and the mean 5-year survival rate has risen to 40-60% through improved selection of patients, surgical techniques, and perioperative care (3)(4)(5)(6)(7)(8)(9)(10) . However, not much is known about the morbidity related to these procedures, especially in older women.…”

mentioning

confidence: 99%

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer

Roos

Eijkeren

Boon

et al. 2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer

Roos¹,

Eijkeren²,

Boon³

et al. 2005

Int J Gynecol Cancer

View full text Add to dashboard Cite

Pelvic exenteration is used as therapeutic option for advanced or recurrent cancer in the pelvis. We determined the complications of and the survival after pelvic exenteration. The study was performed as a retrospective cohort (n = 62) study from January 1, 1989, until January 1, 2000. Descriptive statistics were used. Survival was estimated according to the Kaplan-Meier life table. The operative mortality was 1.6%. Seventy-five percent of the patients had postoperative complications of which ileus and urinary tract infection were the most common. Late complications occurred in 83% of the patients. Recurrent disease was observed in 38% of the women, whereas 50% had died on January 1, 2000. Five-years disease-free and overall survival were 42% (confidence interval [CI] +/- 14%) and 46% (CI +/- 14%), respectively. Elderly patients (> 70 years old) do not experience more complications. Despite considerable morbidity, pelvic exenteration is a therapeutic option for survival, even for patients of 70 years and older.

show abstract

“…With a central recurrence, exenterative surgery in carefully selected women could give a 5-year survival of 40-60%. 27,30 If there is recurrence after surgery, the usual treatment is radiotherapy with or without platinum-based chemotherapy. The role of chemotherapy is mainly for palliation to relieve symptoms as well as to prolong survival.…”

Section: Recurrent Cervical Cancermentioning

confidence: 99%

The current management of cervical cancer

Abu

Nunns

Davies

et al. 2004

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Cervical cancer is a common cause of death worldwide. In the developed world, cervical cancer screening has successfully reduced the incidence of and mortality from the disease. Mortality remains high among developing nations. Over the past decade, there have been various developments in management strategies, based on currently available evidence. This review explores such evidence and recommends current management strategies, including fertilitysparing surgical options for early‐stage disease.

show abstract

Pelvic exenteration: a review of the Gateshead experience 1974–1992

Cited by 27 publications

References 13 publications

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer

Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer

The current management of cervical cancer

Contact Info

Product

Resources

About